Product Details Supplier Info More products

Novozymes Biopharma has announced the construction of a cGMP facility that will enable its Bacillus-based hyaluronic acid, Hyacare, to be used within the biomedical and pharmaceutical industries.

The cGMP facility will be constructed at the company’s existing site in Tianjin, China, and will produce bHA products to pharmaceutical grade Q7.

Hyacare is a recombinant source of hyaluronic acid.

It is produced using Novozymes Biopharma’s safe fermentation and purification technology, which results in a consistent and pure product.

The Hyacare process is free of animal-derived components and is produced without the use of organic solvents.

HA is traditionally derived from rooster combs or from strains of streptococcal bacteria, which may potentially result in safety risks from animal proteins, viruses or endotoxins.

Novozymes Biopharma developed this animal-free HA using a non-pathogenic method by fermentation of a well-documented production strain, Bacillus subtilis.

The Bacillus strain is a well-characterised, endotoxin-free organism that is generally regarded as safe by the US Food and Drug Administration (FDA).

Bacillus HA is identical to natural HA and will be backed by a safety package to support API applications.

Novozymes Biopharma UK

View full profile